Blueprint Medicines

Blueprint Medicines is a biopharmaceutical company focused on developing medicines for patients with genomically defined cancers and rare diseases. The company's drug candidates are: avapritinib, its key drug candidate, which is an orally available and selective inhibitor that targets KIT and PDGFRa mutations; BLU-554, an orally available and selective inhibitor that targets FGFR4, a kinase that is aberrantly activated in a defined subset of patients with hepatocellular carcinoma, a type of liver cancer; and BLU-667, which targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations, and RET resistance mutations.
  • TickerBPMC
  • ISINUS09627Y1091
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

2 directors sold after exercising options/sold

Two Directors at Blueprint Medicines Corp sold after exercising options/sold 9,563 shares at between 100.086USD and 100.746USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading a...

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

Increased risk weighs on BLUEPRINT MDC.CORP., penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of BLUEPRINT MDC.CORP. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date April 12, 2019, the closing price was USD 80.43 and its target price was estimated at USD 58.31.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch